NRI and SIRI are the optimal combinations for prognostic risk stratification in patients with non-small cell lung cancer after EGFR-TKI therapy
NRI and SIRI were the best combination models for predicting clinical outcomes of NSCLC patients receiving EGFR-TKI treatment, which may be a novel biomarker for supplement risk stratification in NSCLC patients.
Authors
- Guolong Liu (ORCID: https://orcid.org/0000-0002-8336-1703)
- Peipei Wang (ORCID: https://orcid.org/0000-0001-7201-4928)
- Xia Liu (ORCID: https://orcid.org/0000-0002-9768-2583)
Institutions
- Guangzhou First People's Hospital (CN)
- First Affiliated Hospital of Jinan University (CN)
- South China University of Technology (CN)
- Guangzhou Medical University (CN)
Publication Details
- Journal
- Clinical & Translational Oncology
- Published
- 2024-09-20
- DOI
- https://doi.org/10.1007/s12094-024-03735-7
- Citations
- 4
- Primary Topic
- Inflammatory Biomarkers in Disease Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 1.13